Profile data is unavailable for this security.
About the company
Shanghai Fosun Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates in five segments. Pharmaceutical segment is mainly engaged in the manufacturing of innovative drugs, mature pharmaceutical products and vaccines. Medical Devices and Medical Diagnostics segment is mainly engaged in the manufacturing and sales of medical cosmetic devices such as molecular diagnosis, immunodiagnosis, and microbial diagnosis. Medical Health Services segment is mainly engaged in the operation of an online and offline integrated medical service platform. Pharmaceutical Distribution and Retail segment is mainly engaged in the wholesale and retail of pharmaceutical products. Others segment is engaged in other pharmaceutical-related businesses. The Company's products are mainly used in the treatment of tumors, immunity, central nervous system and other fields.
- Revenue in HKD (TTM)44.14bn
- Net income in HKD2.01bn
- Incorporated1995
- Employees39.31k
- LocationShanghai Fosun Pharmaceutical Group Co LtdBuilding A, No. 1289 Yishan RoadSHANGHAI 200233ChinaCHN
- Phone+86 2 133987870
- Fax+86 2 133987871
- Websitehttps://www.fosunpharma.com/
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Oct 2024 | 20.79m | 3.77% |
| BlackRock Fund Advisorsas of 25 Apr 2024 | 8.36m | 1.52% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 6.82m | 1.24% |
| BlackRock Advisors (UK) Ltd.as of 25 Apr 2024 | 6.08m | 1.10% |
| Martin Currie Investment Management Ltd.as of 30 Sep 2024 | 3.78m | 0.69% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 3.49m | 0.63% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 3.31m | 0.60% |
| Wilmington Trust Investment Management LLCas of 31 Dec 2023 | 2.69m | 0.49% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 2.64m | 0.48% |
| EARNEST Partners LLCas of 30 Sep 2024 | 1.79m | 0.32% |
